Quick Answer
Immix Biopharma, Inc. reported Diluted EPS of $0.89 per share (loss) for fiscal year 2025.
Immix Biopharma, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.89 | -17.1% |
| 2024 | -$0.76 | +14.6% |
| 2023 | -$0.89 | -50.8% |
| 2022 | -$0.59 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.24 | +0.0% | -9.1% |
| June 30, 2025 | -$0.22 | -46.7% | -46.7% |
| March 31, 2025 | -$0.15 | +31.8% | +37.5% |
| September 30, 2024 | -$0.24 | -4.3% | -60.0% |
| June 30, 2024 | -$0.15 | +37.5% | +31.8% |
| March 31, 2024 | -$0.22 | -22.2% | +4.3% |
| September 30, 2023 | -$0.23 | -109.1% | +4.2% |
| June 30, 2023 | -$0.24 | -118.2% | -33.3% |
- Immix Biopharma, Inc. showed a decrease of -17.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Immix Biopharma, Inc.’s diluted eps has declined by 50.8% (from $0.59 per share (loss) to $0.89 per share (loss)).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: